Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
Primary Industries
- Medical
- Diagnostic
- Cancer
- bone marrow
- Tissue
- Device
- Technical Know How
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 301243
Under the Agreement, each party has an undivided joint ownership interest in all of the patents and other intellectual property rights for such Target-Selector technology, The license is exclusive, worldwide, irrevocable, and sublicensable.
The patent relates to reagents and kits where the sample types are tissue, whole blood, bone marrow, cerebrospinal fluid or derivatives of any of the foregoing.
The field of use is oncology, all applications in the fields of oncology clinical testing and oncology diagnostics, including both laboratory developed tests and IVD tests as applied to the oncology field, and oncology basic and clinical research.
IPSCIO Record ID: 352725
The Parties desire for Licensee to have the exclusive right to Exploit the Pooled Patents in the NIPT IVD Field.
Licensee will have
– the exclusive, worldwide, sublicensable right under the Pooled Patents to Exploit NIPT IVD Products in the NIPT IVD Field,
– the exclusive, worldwide, sublicensable right under the Pooled Patents, excluding the Isis Patents, to Exploit NIPT LDT Tests in the NIPT LDT Field, subject to the non-exclusive rights granted to, or reserved by, the Licensor Parties, and
– the nonexclusive, worldwide, sublicensable right under the Isis Patents to Exploit NIPT LDT Tests in the NIPT LDT Field.
Licensor on behalf of itself and its Affiliates, grants to Licensee and its Affiliates an exclusive, irrevocable and perpetual, non-transferable and non-assignable, worldwide license, with the exclusive right to grant sub licenses, under the Licensor Owned Patents and Isis Patents, to Exploit NIPT LDT Tests in the NIPT LDT Field and to Exploit NIPT IVD Products in the NIPT IVD Field, provided that the license is Royalty bearing with respect to NIPT IVD Products and the license is Test Fee-bearing with respect to NIPT LDT Tests.
NIPT IVD Product means a distributable in vitro diagnostic device that has either received applicable Regulatory Approval for sale and use to conduct or perform, in whole or in part, NIPT or is otherwise particularly labeled and marketed for use to conduct or perform NIPT, in whole or in part, excluding general purpose products and components labeled for research use only.
Licensor noninvasive prenatal testing (NIPT) is a chromosome counting method that analyzes genetic information in fetal cell-free DNA in maternal blood to determine risk for specific fetal chromosomal and subchromosomal abnormalities.
IPSCIO Record ID: 315834
For the Research, Licensee shall perform primary testing associated with a validation study of its laboratory -developed test using the Licensed Technology in connection with MD Anderson Cancer Center or an equivalent academic cancer center (with the exception of tissue biopsy) including expression testing, the PSA and send-out of the PCA-3, the Validation Study. Licensee shall have the right to perform research on remnants after all testing required for the Validation Study is completed, and will be provided reasonable access to the patient data related to the applicable samples. Licensor shall obtain IRB approval for the study with MD Anderson Cancer Center by February 28, 2009 or, with an equivalent academic institution by June 30, 2009.
For the Purchasing Rights, upon issuance of FDA clearance or approval of an in vitro diagnostic kit using the Licensed Technology (IVD Kit), Licensee shall have the obligation to purchase IVD Kits for reference laboratory use from Licensor’s designated manufacturer or distributor pursuant to a purchasing agreement between Licensee and the applicable manufacturer or distributor, provided however that Licensor shall negotiate to cause such manufacturer or distributor to provide Most Favored Terms to Licensee.
The patents include
Method of Identifying Patterns in Biological Systems and Uses Thereof;
Biomarkers Overexpressed in Prostate Cancer;
Biomarkers Upregulated in Prostate Cancer; and,
Methods for Screening, Predicting and Monitoring Prostate Cancer.
Licensees focus is developing a test for and performing clinical laboratory diagnostic testing using gene biomarkers detected in patient urine samples for differentiating clinically significant prostate cancer from other prostate conditions.
